MMIT’s Inaugural State of the Industry Survey

Fortunately for patients, there are many pharmaceutical and biotech companies working hard to bring innovative therapies to market. But in today’s reality of increasing payer restrictions and barriers to access, how can companies make sure that much-needed treatments get into the hands of patients in need?

In an attempt to shed light on the current and future patient access landscape, we conducted a comprehensive industry survey alongside our sister company, The Dedham Group. Our goal was to better understand how pharma leaders today are planning for potential access problems tomorrow.

Over 300 pharma and biotech leaders weighed in on both existing and future barriers to access, what keep them awake at night, and what gets them going in the morning. By sharing these insights and our key perspectives on what it all means, our hope is to equip companies with the information they need to power their commercial decision-making—and ensure the right patient gets access to the right treatment at the right time.